TE-8 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC)

The TE-8 xenograft model offers a robust preclinical platform for evaluating therapeutic candidates against esophageal squamous cell carcinoma (ESCC), faithfully recapitulating the histopathological and molecular features of human disease in an immunodeficient host. Alfa Cytology provides comprehensive TE-8 xenograft model services tailored to your drug development pipeline, combining rigorous in vivo pharmacology expertise with streamlined study execution to accelerate your preclinical research from candidate selection to IND-enabling studies.

Overview of TE-8 Xenograft Model for Esophageal Squamous Cell Carcinoma (ESCC)

The TE-8 cell line was established from a moderately differentiated esophageal squamous cell carcinoma and has been extensively validated as a representative model for ESCC research. When propagated as a xenograft in immunodeficient mice, TE-8 tumors retain the characteristic histological architecture of human ESCC, including squamous differentiation patterns, keratin pearl formation, and invasive growth behavior. The model exhibits consistent tumorigenicity with predictable growth kinetics, making it suitable for longitudinal efficacy studies and biomarker investigations. Molecularly, TE-8 harbors alterations commonly observed in ESCC, including TP53 mutations and EGFR pathway activation, providing a genetically relevant background for testing targeted therapeutics.

Xenograft models derived from TE-8 cells have demonstrated utility in evaluating conventional chemotherapeutics, targeted agents, and combination regimens. The model supports both subcutaneous and orthotopic implantation strategies, with subcutaneous models offering convenient tumor monitoring and orthotopic variants enabling assessment of locoregional invasion and metastatic potential. Tumor-bearing animals typically develop palpable masses within 10-14 days post-implantation, with linear growth phases suitable for treatment window studies. Histopathological examination of established xenografts reveals preserved expression of squamous markers such as cytokeratin 5/6 and p63, confirming faithful recapitulation of the parental tumor phenotype throughout serial passaging.

Figure 1. Cytotoxic effects of Theracurmin on ESCC cells. (Mizumoto, Ayaka, et al., 2019)

Cell Line Information: TE-8

TE-8 is a human esophageal squamous cell carcinoma cell line originally derived from a Japanese patient with moderately differentiated ESCC. The cell line has been authenticated and distributed through international cell banks including RIKEN BRC (RCB2098) and is widely utilized in ESCC research programs worldwide. The following table summarizes the key characteristics of the TE-8 cell line:

Our Services

Alfa Cytology leverages the TE-8 xenograft platform to deliver robust, data-driven preclinical insights for your ESCC therapeutic programs. Our integrated service portfolio spans model establishment, in vivo pharmacology, biomarker analysis, and comprehensive histopathological evaluation, ensuring seamless progression from proof-of-concept to regulatory submission. With stringent quality control protocols and dedicated project management, we provide reproducible, publication-ready data that meets the exacting standards of global pharmaceutical and biotechnology partners.

Workflow of TE-8 Xenograft Model Construction

The construction of TE-8 xenograft models at Alfa Cytology follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable pharmacological readouts. Each stage is executed under GLP-compliant protocols with rigorous documentation and quality assurance checkpoints.

1. Cell Culture and Preparation: TE-8 cells are maintained in exponential growth phase under authenticated culture conditions. Prior to implantation, cells are harvested at optimal confluence, viability is confirmed by trypan blue exclusion (>95%), and mycoplasma negativity is verified by PCR.
2. Matrigel Preparation: Cells are resuspended in a defined ratio of serum-free medium and high-concentration Matrigel (typically 1:1 v/v) to enhance initial engraftment and support extracellular matrix interactions critical for tumor establishment.
3. Animal Preparation and Implantation: Immunodeficient mice (NSG, SCID, or nude) are acclimatized for 7 days. Subcutaneous implantation is performed via injection into the flank region (typically 5x10^6 cells in 100-200 microL volume). Orthotopic models involve surgical exposure of the cervical esophagus with direct intramural injection under microscopic guidance.
4. Post-Implantation Monitoring: Animals are monitored daily for body weight, clinical signs, and tumor palpation. Tumor dimensions are measured by caliper twice weekly once palpable, and volumes are calculated using the modified ellipsoid formula (V = 0.5 x L x W^2).
5. Treatment Initiation: When tumors reach the target volume (typically 100-150 mm^3), animals are randomized into treatment cohorts based on tumor volume and body weight. Test articles are administered according to the predefined dosing regimen (route, frequency, duration).
6. Endpoint Analysis: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E, IHC), molecular profiling (Western blot, qPCR, RNA-seq), and pharmacokinetic assessment. Blood samples are collected for hematology and clinical chemistry if required.
7. Data Compilation and Reporting: All raw data, statistical analyses, and representative images are compiled into a comprehensive study report with tumor growth curves, waterfall plots, body weight trajectories, and histopathological summaries.

Figure 2: Schematic workflow illustrating the derivation and construction of the TE-8 Xenograft Model at Alfa Cytology.

Case Study-TE-8 Xenograft Model Development

In a recent engagement, Alfa Cytology established TE-8 subcutaneous xenografts in NSG mice to evaluate the efficacy of a novel EGFR-targeting therapeutic agent in combination with standard-of-care chemotherapy. The study achieved 100% tumor take rate with consistent growth kinetics across all animals. Treatment cohorts demonstrated dose-dependent tumor growth inhibition, with the combination arm showing superior anti-tumor activity compared to monotherapy. Comprehensive biomarker analysis revealed modulation of downstream signaling pathways consistent with the proposed mechanism of action. Histopathological evaluation confirmed extensive necrosis and reduced proliferation indices in responder tumors. This case exemplifies the utility of the TE-8 platform for generating translational preclinical data to support IND-enabling studies and clinical trial design.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a premier preclinical CRO partner through specialized expertise in oncology model development, rigorous quality standards, and client-centric service delivery. Our TE-8 xenograft program is designed to maximize the translational value of your preclinical data while minimizing study timelines.

• Proven track record with authenticated TE-8 cell lines and established xenograft protocols ensuring consistent tumor take rates and reproducible growth kinetics.
• Flexible study designs accommodating subcutaneous, orthotopic, and patient-derived xenograft (PDX) configurations to address diverse scientific questions.
• Integrated biomarker and histopathology capabilities enabling mechanistic insights and pharmacodynamic endpoint evaluation within a single service provider.
• GLP-compliant operations with comprehensive quality assurance, including IACUC-approved protocols, veterinary oversight, and detailed audit trails.
• Dedicated project management ensuring transparent communication, milestone-driven execution, and rapid turnaround from study initiation to final report delivery.
• Competitive pricing structures without compromising scientific rigor, optimized for biotechnology startups, mid-size pharmaceutical companies, and academic research groups.

Contact Us

Ready to advance your ESCC therapeutic pipeline with robust preclinical data? Please reach out to us today via our inquiry form or email to learn more about our TE-8 Xenograft Model services.

For research use only. Not intended for any clinical use.